Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00226239
Status:
COMPLETED
Last Update Posted:
2017-07-11
First Post:
2005-09-22
Brief Title:
Docetaxel Cetuximab and Cisplatin Followed by Radiation Cetuximab and Cisplatin in Head and Neck Cancer
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
A Phase II Trial of Docetaxel Cetuximab C225 and Cisplatin Followed by Radiation Cetuximab and Cisplatin in Locally Advanced Head and Neck Cancer
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if the addition of a unique targeted agent called Cetuximab also known as C225 and Erbitux can increase the effectiveness of standard treatment with chemotherapy and radiation
Detailed Description:
This research study involves the use of a combination of two chemotherapies cisplatin and docetaxel which have been known to shrink head and neck cancers and are a commonly used treatment for this type of cancer This combination will then be followed by radiation and more chemotherapy
The purpose of this study is to see whether this combination of chemotherapy and radiation with the addition of Cetuximab can improve control of disease and collect information on what side effects this combination therapy may have In addition biologic factors markers will be studied that may help to predict and treat head and neck cancer patients in the future
The purpose of this study is to see whether this combination of chemotherapy and radiation with the addition of Cetuximab can improve control of disease and collect information on what side effects this combination therapy may have In addition biologic factors markers will be studied that may help to predict and treat head and neck cancer patients in the future
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None